Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

BACKGROUND: Daikenchuto (DKT) has widely been used to improve abdominal symptoms by being expected to accelerate bowel motility. The purpose of this study is to examine the efficacy and safety of DKT for prevention of ileus and associated gastrointestinal symptoms after total gastrectomy. STUDY DESIGN: Two hundred and forty-five gastric cancer patients who underwent total gastrectomy were enrolled. Patients received either DKT (15.0 g/d) or matching placebo from postoperative days 1 to 12. Primary end points were time to first flatus, time to first bowel movement (BM), and frequency of BM. Secondary end points included quality of life, C-reactive protein level, symptoms indicative of a severe gastrointestinal disorder, and incidence of postoperative ileus. RESULTS: A total of 195 patients (DKT, n = 96; placebo, n = 99) were included in the per-protocol set analysis. There were no significant differences between the groups in terms of patient background characteristics. Median time to first BM was shorter in the DKT group than in the placebo group (94.7 hours vs 113.9 hours; p = 0.051). In patients with high medication adherence, median time to first BM was significantly shorter in the DKT group than in the placebo group (93.8 hours vs 115.1 hours; p = 0.014). Significantly fewer patients in the DKT group had ≥2 symptoms of gastrointestinal dysfunction than those in the placebo group on postoperative day 12 (p = 0.026). CONCLUSIONS: Administration of DKT during the immediate postoperative period after total gastrectomy appears to promote early recovery of postoperative bowel function.

An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer.

BACKGROUND: Pulmonary complications occur most frequently following a transthoracic esophagectomy for esophageal cancer and would get to be lethal occasionally. In this study, we sought to determine the effect of respiratory physiotherapy, corticosteroid administration, and the use of the video-assisted thoracoscopic (VATS) esophagectomy with a small thoracotomy incision, on the incidence of pulmonary complications following a transthoracic subtotal esophagectomy. MATERIALS AND METHODS: Approximately 184 patients who had undergone a right transthoracic subtotal esophagectomy for squamous cell carcinoma of the thoracic esophagus were studied. To reduce the incidence of pulmonary complications, we performed clinical trials using respiratory physiotherapy, corticosteroid administration, and the VATS-esophagectomy surgical technique. RESULTS: The independent risk factors for pulmonary complications in the multivariate logistic regression analysis were not administering corticosteroids, blood loss greater than 630 ml, and not providing respiratory physiotherapy. In addition, the use of a small surgical incision, less than 10 cm, for the thoracotomy had no effect on the prevention of pulmonary complications. CONCLUSIONS: We concluded that patients with thoracic esophageal cancer could undergo a three-field dissection in comparative safety if the patients were provided with corticosteroid medication in the perioperative period, if the patients received sufficient respiratory physiotherapy, and if surgical blood loss was reduced.

Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer.

BACKGROUND AND OBJECTIVES: Various adjuvant chemotherapy regimens have been proposed for patients with advanced gastric cancer; however, the majority of these trials failed to show a clear survival benefit over surgery alone. In this study, the feasibility and efficacy of a strategy of extended surgery combined with individualized adjuvant chemotherapy for advanced gastric cancer with serosal invasion and nodal involvement was examined. PATIENTS AND METHODS: Sixty-four patients with advanced gastric cancer underwent gastrectomy with extended lymph node dissection. After surgery, a chemosensitivity test by MTT assay, using highly purified tumor cells, was performed, and the patients received individualized adjuvant chemotherapy on the basis of the results of this chemosensitivity test. RESULTS: Overall survival in the chemosensitivity-guided chemotherapy (CSC) group was significantly better than the standard chemotherapy (SC) and the no-chemotherapy (NC) group (p<0.05). In patients with stage IV disease, the 5-year survival rate was 38.1% in the CSC group and 0% in the SC + NC group, respectively, with a significant difference being observed in the two survival curves (p<0.01). In patients with paraaortic node involvement, survival in the CSC group was significantly better than that in the SC + NC group (p<0.01). On the other hand, in patients without paraaortic node involvement, no survival difference was observed between the two groups. CONCLUSION: The strategy of extended surgery combined with individualized adjuvant chemotherapy offers a favorable survival outcome for advanced gastric cancer patients with serosal invasion and nodal involvement.